We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
-$295M
Cap. Flow
-$688M
Cap. Flow %
-3.02%
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$58.8M
2
LEGN icon
Legend Biotech
LEGN
+$52.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$34M
4
JBIO
Jade Biosciences
JBIO
+$32.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.9M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$611M
2
NVTA
Invitae Corporation
NVTA
+$179M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$33.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$32.4M
5
ALT icon
Altimmune
ALT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERS icon
26
Cerus
CERS
$575M
$81M 0.36%
13,713,195
– –
DBVT
27
DBV Technologies
DBVT
$795M
$79.8M 0.35%
1,461,426
– –
RYTM icon
28
Rhythm Pharmaceuticals
RYTM
$7.38B
$75.6M 0.33%
3,863,239
+383,366
+11% +$7.96M
TIL icon
29
Instil Bio
TIL
$48.9M
$75.2M 0.33%
194,685
– –
LEGN icon
30
Legend Biotech
LEGN
$3.65B
$68.3M 0.3%
1,664,534
+1,548,908
+1,340% +$52.6M
NBIX icon
31
Neurocrine Biosciences
NBIX
$18.3B
$65.9M 0.29%
676,975
– –
NRIX icon
32
Nurix Therapeutics
NRIX
$2.46B
$65.1M 0.29%
2,454,082
– –
INSM icon
33
Insmed
INSM
$22.5B
$61.4M 0.27%
2,156,001
– –
ALLK
34
DELISTED
Allakos
ALLK
$60M 0.26%
703,050
– –
ZYME icon
35
Zymeworks
ZYME
$1.62B
$59.3M 0.26%
1,708,472
– –
HZNP
36
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$56.1M 0.25%
599,110
– –
FMTX
37
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$50.4M 0.22%
2,024,876
– –
IMTX icon
38
Immatics
IMTX
$1.21B
$49.7M 0.22%
4,282,938
+290,182
+7% +$3.41M
MRUS
39
DELISTED
Merus
MRUS
$42.9M 0.19%
2,037,469
– –
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.5B
$42.4M 0.19%
444,444
– –
ADAP
41
DELISTED
Adaptimmune Therapeutics
ADAP
$41.9M 0.18%
9,830,877
– –
KRYS icon
42
Krystal Biotech
KRYS
$10.7B
$41.3M 0.18%
607,735
-152,677
-20% -$10.7M
KNSA icon
43
Kiniksa Pharmaceuticals
KNSA
$6.21B
$39M 0.17%
2,799,577
– –
FLGT icon
44
Fulgent Genetics
FLGT
$560M
$37M 0.16%
401,016
– –
AXSM icon
45
Axsome Therapeutics
AXSM
$11.9B
$36.4M 0.16%
539,057
-89,357
-14% -$5.36M
NGNE icon
46
Neurogene
NGNE
$656M
$35.3M 0.15%
191,087
– –
BCAB icon
47
BioAtla
BCAB
$5.39M
$35M 0.15%
16,500
– –
ADCT icon
48
ADC Therapeutics
ADCT
$141M
$34.5M 0.15%
1,418,107
– –
ALGS icon
49
Aligos Therapeutics
ALGS
$26.5M
$32.8M 0.14%
64,400
– –
JBIO
50
Jade Biosciences
JBIO
$1.18B
$32.6M 0.14%
+40,816
New +$32.6M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Baker Bros. Advisors held 135 positions worth $22.8B, down 1.3% from $23.1B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors withdrew a net $688M in Q2 2021, closing 15 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $611M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Verve Therapeutics worth $85.3M.

  • Baker Bros. Advisors's largest Q2 2021 buy was Verve Therapeutics: 1,416,530 shares worth $85.3M.
  • Baker Bros. Advisors added most to Legend Biotech in Q2 2021, an estimated $52.6M increase.
  • Baker Bros. Advisors's biggest Q2 2021 reduction was Invitae Corporation, cutting an estimated $179M.
  • Baker Bros. Advisors fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $611M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $22.8B portfolio in Q2 2021.
  • Baker Bros. Advisors opened 6 new positions and closed 15 in Q2 2021.
  • Baker Bros. Advisors's portfolio value fell 1.3% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.